Potential Ulcerative Colitis Therapy Advancing in Clinical Development

Potential Ulcerative Colitis Therapy Advancing in Clinical Development
Tiziana Life Sciences recently announced its plan for further development of foralumab, the company’s fully human anti-CD3 antibody, with a first evaluation of the compound in two clinical indications: graft vs. host disease, and ulcerative colitis, an inflammatory bowel disease (IBD). Foralumab is the only fully human engineered anti-CD3 antibody currently in clinical development, the company reports. The compound is being tested in Phase 2 studies and has potential applications in a wide array of autoimmune and inflammatory diseases like IBD and ulcerative colitis, as well as for type 1 diabetes, rheumatoid arthritis, psoriasis, and multiple sclerosis. Tiziana also announced the addition of two new members to its Scientific Advisory Board team, Professors Howard Weiner, MD, and Kevan Herold, MD, who will focus on a clinical development plan for foralumab. Dr. Weiner is the co-director of the Ann Romney Center for Neurologic Diseases at Brigham & Women's Hospital in Boston, and a professor of Neurology at the Harvard Medical School. He has investigated the mucosal immune system for the treatment of autoimmune diseases, and pioneered the use of anti-CD3 to induce regulatory immune T cells for the treatment of such diseases. Dr. Weiner was also one of the pioneers in immunotherapy for MS treatment and has done significant research on immune mechanisms in nervous system diseases like Alzheimer’s and amyotrophic lateral sclerosis (ALS), and in strokes and brain tumors, according to a press release. Dr. Herold is a professor of Immunobiology and Endocrinology at Yale University, and deputy director, Yale Center for Clinical Investigation, director of the Yale Diabetes Center, and director of the TrialNet Center at Yale. His work has concentrated on th
Subscribe or to access all post and page content.